REMspace Launches LucidMe — A Breakthrough Smart Sleep Mask With AI-Powered Sleep, Snoring, and Dream Features
We envision smart sleep masks becoming as essential as smartphones — helping people improve their health, reduce stress, and unlock the hidden potential of their dreams.
Share
Combining sleek design with powerful AI-driven technology, LucidMe offers an unprecedented set of features in a single wearable:
Faster Sleep Onset: Five programs help users fall asleep up to 2–3× faster.
Snore Reduction: Built-in sensors detect snoring and prompt a gentle position change.
Smart Wake-Up: Natural light and sound stimulation that can be snoozed with a simple head gesture.
Sleep Stage Tracking: Real-time sleep monitoring with app-based sleep quality analysis.
Lucid Dream Induction: Innovative methods during sleep onset, REM phases, and wake transitions.
Meditation Guidance: Adaptive breath and focus training supported by audio-visual feedback.
"The LucidMe mask is a major leap forward in how we engage with sleep,' said Michael Raduga, CEO and founder of REMspace. 'This isn't just a tracker; it's an active sleep coach that will redefine nightly rest and open doors to conscious dreaming. We envision smart sleep masks becoming as essential as smartphones — helping people improve their health, reduce stress, and unlock the hidden potential of their dreams.'
The mask is the result of two years of intensive research and development by a team of experienced sleep scientists and engineers. With continuous software updates, LucidMe will continue to evolve with new features and deeper AI integration.
LucidMe is available now for $245 at www.remspace.net, with global shipping starting immediately.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 days ago
- Business Wire
Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today issued the following statement: Just before 6:00 p.m. ET today, the U.S. Food and Drug Administration (FDA) issued a press release announcing an investigation into the death of an eight-year-old Duchenne muscular dystrophy (Duchenne) patient who had received ELEVIDYS (delandistrogene moxeparvovec) gene therapy. The death of this patient was deemed unrelated to treatment with ELEVIDYS. As reported yesterday by Naomi Kresge at Bloomberg News: Roche Holding AG says the recent death of a patient in Brazil who had been treated with gene therapy Elevidys for Duchenne muscular dystrophy is unrelated to the treatment. * The boy wasn't a clinical trial participant; reporting physician assessed his death as being unrelated to the gene therapy, Roche says in statement * Death was reported to health authorities * Roche, which markets Sarepta's Duchenne treatment Elevidys outside the US, declines to comment on the boy's age or details of the case Sarepta reported this event to FDA on June 18, 2025, via the FDA's postmarketing electronic database, FAERS. At Sarepta, patient safety and well-being are always our top priority. We are committed to upholding the highest safety standards for all of our therapies, and do so in accordance with applicable law and commitment to full regulatory transparency. ELEVIDYS is the only approved gene therapy for families and children devastated by Duchenne, a rare, progressive and ultimately fatal disease. We remain committed to working closely with the FDA to ensure that all decisions are grounded in science and the best interests of patients, considering the compelling need of these families to access disease-modifying therapy. About ELEVIDYS (delandistrogene moxeparvovec-rokl) ELEVIDYS (delandistrogene moxeparvovec-rokl) is a single-dose, adeno-associated virus (AAV)-based gene transfer therapy for intravenous infusion designed to address the underlying genetic cause of Duchenne muscular dystrophy – mutations or changes in the DMD gene that result in the lack of dystrophin protein – through the delivery of a transgene that codes for the targeted production of ELEVIDYS micro-dystrophin in skeletal muscle. ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). IMPORTANT SAFETY INFORMATION CONTRAINDICATION: ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. WARNINGS AND PRECAUTIONS: Infusion-related Reactions: Infusion-related reactions, including hypersensitivity reactions and anaphylaxis, have occurred during or up to several hours following ELEVIDYS administration. Closely monitor patients during administration and for at least 3 hours after the end of infusion. If symptoms of infusion-related reactions occur, slow, or stop the infusion and give appropriate treatment. Once symptoms resolve, the infusion may be restarted at a lower rate. ELEVIDYS should be administered in a setting where treatment for infusion-related reactions is immediately available. Discontinue infusion for anaphylaxis. Acute Serious Liver Injury: Acute serious liver injury has been observed with ELEVIDYS, and administration may result in elevations of liver enzymes (such as GGT, GLDH, ALT, AST) or total bilirubin, typically seen within 8 weeks. Patients with preexisting liver impairment, chronic hepatic condition, or acute liver disease (e.g., acute hepatic viral infection) may be at higher risk of acute serious liver injury. Postpone ELEVIDYS administration in patients with acute liver disease until resolved or controlled. Prior to ELEVIDYS administration, perform liver enzyme test and monitor liver function (clinical exam, GGT, and total bilirubin) weekly for the first 3 months following ELEVIDYS infusion. Continue monitoring if clinically indicated, until results are unremarkable (normal clinical exam, GGT, and total bilirubin levels return to near baseline levels). Systemic corticosteroid treatment is recommended for patients before and after ELEVIDYS infusion. Adjust corticosteroid regimen when indicated. If acute serious liver injury is suspected, consultation with a specialist is recommended. Immune-mediated Myositis: In clinical trials, immune-mediated myositis has been observed approximately 1 month following ELEVIDYS infusion in patients with deletion mutations involving exon 8 and/or exon 9 in the DMD gene. Symptoms of severe muscle weakness, including dysphagia, dyspnea, and hypophonia, were observed. Limited data are available for ELEVIDYS treatment in patients with mutations in the DMD gene in exons 1 to 17 and/or exons 59 to 71. Patients with deletions in these regions may be at risk for a severe immune-mediated myositis reaction. Advise patients to contact a physician immediately if they experience any unexplained increased muscle pain, tenderness, or weakness, including dysphagia, dyspnea, or hypophonia, as these may be symptoms of myositis. Consider additional immunomodulatory treatment (immunosuppressants [e.g., calcineurin-inhibitor] in addition to corticosteroids) based on patient's clinical presentation and medical history if these symptoms occur. Myocarditis: Acute serious myocarditis and troponin-I elevations have been observed following ELEVIDYS infusion in clinical trials. If a patient experiences myocarditis, those with pre-existing left ventricle ejection fraction (LVEF) impairment may be at higher risk of adverse outcomes. Monitor troponin-I before ELEVIDYS infusion and weekly for the first month following infusion and continue monitoring if clinically indicated. More frequent monitoring may be warranted in the presence of cardiac symptoms, such as chest pain or shortness of breath. Advise patients to contact a physician immediately if they experience cardiac symptoms. Preexisting Immunity against AAVrh74: In AAV-vector based gene therapies, preexisting anti-AAV antibodies may impede transgene expression at desired therapeutic levels. Following treatment with ELEVIDYS, all patients developed anti-AAVrh74 antibodies. Perform baseline testing for presence of anti-AAVrh74 total binding antibodies prior to ELEVIDYS administration. ELEVIDYS administration is not recommended in patients with elevated anti-AAVrh74 total binding antibody titers greater than or equal to 1:400. Adverse Reactions: The most common adverse reactions (incidence ≥5%) reported in clinical studies were vomiting, nausea, liver injury, pyrexia, and thrombocytopenia. Report negative side effects of prescription drugs to the FDA. Visit or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782). For further information, please see the full Prescribing Information. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, please visit or follow us on LinkedIn, X, Instagram and Facebook. Forward-Looking Statements This statement contains 'forward-looking statements.' Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as 'believe,' 'anticipate,' 'plan,' 'expect,' 'will,' 'may,' 'intend,' 'prepare,' 'look,' 'potential,' 'possible' and similar expressions are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements relating to our future operations, research and development programs, clinical trials and ELEVIDYS. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: our products or product candidates may be perceived as insufficiently effective, unsafe or may result in unforeseen adverse events; our products or product candidates may cause undesirable side effects that result in significant negative consequences following any marketing approval; the possible impact of regulations and regulatory decisions by the FDA and other regulatory agencies on our business; and those risks identified under the heading 'Risk Factors' in our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company, which you are encouraged to review. Any of the foregoing risks could materially and adversely affect the Company's business, results of operations and the trading price of Sarepta's common stock. For a detailed description of risks and uncertainties Sarepta faces, you are encouraged to review the SEC filings made by Sarepta. We caution investors not to place considerable reliance on the forward-looking statements contained herein. Sarepta does not undertake any obligation to publicly update its forward-looking statements based on events or circumstances after the date hereof, except as required by law. Internet Posting of Information We routinely post information that may be important to investors in the 'For Investors' section of our website at We encourage investors and potential investors to consult our website regularly for important information about us. Source: Sarepta Therapeutics, Inc.
Business Wire
2 days ago
- Business Wire
CORRECTING and REPLACING Zip Marks Fifth Anniversary with New Offices in San Francisco and New York
SAN FRANCISCO--(BUSINESS WIRE)--Please replace the release dated July 24, 2025, with the following corrected version due to multiple revisions. "The fact that Fortune 500 companies across financial services, telecommunications, healthcare, defense, and retail are choosing a five-year-old company over established vendors speaks to how fundamentally we've reimagined procurement." Share The updated release reads: ZIP MARKS FIFTH ANNIVERSARY WITH NEW OFFICES IN SAN FRANCISCO AND NEW YORK Agentic Procurement Orchestration Leader Doubles Office Footprint Amid Explosive Growth, Surpasses Hundreds of Billions in Processed Requests Zip, the world's leading agentic procurement orchestration platform, today celebrated its fifth anniversary by unveiling expanded offices in San Francisco and New York to accommodate rapid workforce growth driven by unprecedented enterprise adoption. The company has grown from 250 to over 500 employees in the past year alone while securing Global 2000 customers across every major industry. Five years ago, Zip's founders chose to tackle procurement – hardly the most glamorous corner of technological innovation. While others chased trendy markets, Zip focused on the overlooked but critical process of how companies buy what they need. Few shared their vision. Then the world changed. Supply chain disruptions, inflation, and tariffs turned procurement from a back-office afterthought into a C-suite priority. What Zip had been quietly building suddenly became every CEO's top concern. That early vision, combined with five years of relentless innovation and AI leadership, explains why global giants from OpenAI to Discover are choosing Zip to transform their operations. 'Over the past five years, we've built something remarkable – a product so sticky that we've maintained 100% retention across our strategic enterprise customers,' said Rujul Zaparde, Co-founder and CEO of Zip. 'The fact that Fortune 500 companies across financial services, telecommunications, healthcare, defense, and retail are choosing a five-year-old company over established vendors speaks to how fundamentally we've reimagined procurement. We've processed over hundreds of billions in total purchasing request volume since our founding five years ago and we've barely scratched the surface of the global opportunity.' From Zero to $2.2 Billion: Five Years of Unprecedented Growth Zip's journey from startup to enterprise standard represents one of the fastest value creation stories in enterprise software history. In October 2024, the company secured $190 million in Series D funding at a $2.2 billion valuation, marking the largest investment in procurement technology in over two decades and validating Zip's position as the category leader. Since its founding in 2020, Zip has achieved milestones that typically take enterprise software companies decades: Customer Momentum: Trusted by hundreds of global enterprises including AMD, Anthropic, Canva, Coinbase, Discover, Lyft, Northwestern Mutual, OpenAI, Pinterest, Reddit, Sephora, and Snowflake Financial Impact: Generated $4.4 billion in customer savings, with companies averaging 3.6% reduction in total spend savings and 25% in productivity gains Product Innovation: Introduced intake to the world, pioneered orchestration, and launched the industry's first agentic AI suite with 50+ procurement agents. Platform has delivered 4.6 million AI insights and achieved unprecedented engagement for an enterprise software platform with 14 million customer comments Doubling Down on Talent and Geographic Expansion To support its trajectory, Zip is hiring aggressively across all markets while significantly expanding its physical footprint: San Francisco: New headquarters doubles office space to 75,000 square feet, housing 200+ employees from top universities like Stanford and MIT, and companies like Meta, Airbnb, and Scale. The expansion reaffirms Zip's commitment to San Francisco as its global headquarters, investing in the city's downtown revitalization New York: Expanding beyond co-working to establish a permanent Manhattan headquarters, positioning Zip closer to financial services and media giants Global Reach: 60+ employees across EMEA, with continued expansion in London The company has grown from approximately 250 employees to over 500 in the past year, hiring 100+ people per quarter, with spending heavily weighted toward R&D. Five Years of Relentless Innovation Zip's trajectory from introducing intake to pioneering agentic procurement orchestration showcases the company's ability to anticipate and shape market needs: 2020: Founded with a vision to fix broken procurement processes; introduced intake and procurement orchestration to the world, transforming how companies start the procurement process 2021: Revolutionized workflows by launching dynamic approvals and integrating with 25+ enterprise systems including ERPs, CLMs, and GRC platforms 2022: Expanded beyond intake to full Procure-to-Pay capabilities, enabling end-to-end procurement orchestration 2023: Became the first procurement platform to embed generative AI, delivering millions of AI-powered insights to customers 2024: Launched the Integration Platform enabling rapid enterprise deployments; established the Zip AI Lab following landmark Series D funding 2025: Introduced Agentic Procurement Orchestration; unveiled suite of 50+ specialized AI agents that autonomously handle complex procurement tasks from tariff analysis to contract reviews 'Five years ago, we introduced intake to the world. We scaled orchestration. Now, we're shaping the agentic future with 50+ AI agents that are redefining what procurement is capable of,' added Lu Cheng, Zip Co-founder and CTO. 'The most exciting part? We're just getting started.' This fall, Zip will host Zip Forward 2025 at San Francisco's Yerba Buena Center for the Arts, where 750+ procurement and finance leaders will gather under the theme 'Agents of Change.' To request an invitation, please visit About Zip Zip is the world's leading agentic procurement orchestration platform, empowering businesses to accelerate the procurement process, mitigate risk, and drive growth by offering a single front door to unify the teams, tasks, and tools involved in working with suppliers. With Zip, businesses can maximize employee adoption of purchasing policies and increase spend visibility and control. As the leading solution for optimizing business spend, Zip's AI-powered platform is trusted by hundreds of leading enterprises worldwide, including AMD, Anthropic, Coinbase, Discover, Dollar Tree, Instacart, Invesco, Lyft, Northwestern Mutual, Prudential, Reddit, Sephora, and Snowflake to maximize the ROI of every dollar. To learn more, visit
Business Wire
2 days ago
- Business Wire
Earnings Teleconference Moves to Earlier Time on July 29
--(BUSINESS WIRE)--As previously announced, UnitedHealth Group will release its second quarter 2025 financial results on Tuesday, July 29, 2025, before the market opens. The start time for the teleconference has moved to 8:00 a.m. ET, 45 minutes earlier than previously announced, to allow more time for discussion of results with analysts and investors. This call will be webcast on the Investor Relations page of the company's website ( The replay will be available through August 12 on the website. UnitedHealth Group (NYSE: UNH) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone through two distinct and complementary businesses. Optum delivers care aided by technology and data, empowering people, partners and providers with the guidance and tools they need to achieve better health. UnitedHealthcare offers a full range of health benefits, enabling affordable coverage, simplifying the health care experience and delivering access to high-quality care. Visit UnitedHealth Group at and follow UnitedHealth Group on LinkedIn.
